Sign in
CompletedPhase 4

Comparative Immunologic Mechanisms and Microbiome Interactions Following Different Influenza Vaccine Formulations in Older Adults

Key facts

Who runs it
Korea University Guro Hospital
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
121 people enrolled
Started
25 Oct 2025
Ended
31 Aug 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard-Dose Influenza Vaccine
  • MF59-Adjuvanted Influenza Vaccine
  • High-Dose Influenza Vaccine
Record updated
4 September 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age ≥65 years
  • Able and willing to provide informed consent

Who cannot take part

  • Uncontrolled chronic medical conditions
  • Laboratory-confirmed influenza infection within the past 6 months
  • Influenza vaccination within the past 6 months
  • Immunocompromised status

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective, randomized, open-label clinical study aims to evaluate the immunogenicity and underlying immune mechanisms of different influenza vaccine formulations in adults aged ≥65 years. Additionally, the study investigates the role of the gut microbiome in modulating vaccine-induced immune responses and durability.

The 3 groups in the trial

  • Standard-Dose Influenza VaccineExisting treatment, for comparison

    Intervention: Standard-dose quadrivalent influenza vaccine (Vaxigrip®) Dose: 0.5 mL intramuscular injection, single dose

  • MF59-Adjuvanted Influenza VaccineExisting treatment, for comparison

    Intervention: MF59-adjuvanted vaccine (FLUAD®) Dose: 0.5 mL intramuscular injection, single dose

  • High-Dose Influenza VaccineExisting treatment, for comparison

    Intervention: High-dose influenza vaccine (Efluelda®) Dose: 0.7 mL intramuscular injection, single dose

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
4 September 2026